Movement Alert｜PHARMARON Intraday Rise 3.74% in Regular Trading, CXO Rebound and Strong Order Growth Remain in Focus

Market Focus11-05

On November 5, PHARMARON rose 3.74% in Regular Trading, trading at HK$31.18, with turnover of HK$112 million.

The move followed continued market digestion of the company’s latest quarterly results and a broader rebound in CXO names. Recent company disclosures showed first-three-quarter revenue of RMB12.003 billion, up 19.01% year over year, and net profit attributable to shareholders of RMB1.247 billion, up 9.31%. Third-quarter revenue rose 20.94%, while CDMO revenue increased 30% and management indicated new orders in the first three quarters grew by more than 30%.

Recent broker commentary also stayed constructive. One update maintained a Buy rating and projected net profit of RMB2.213 billion, RMB2.934 billion, and RMB3.765 billion for the next three years, while another note said third-quarter growth re-accelerated and kept target prices at HK$46.6 for H shares and RMB64.1 for A shares. Sector sentiment was also supportive, with WUXI APPTEC up 3.44%, WUXI BIO up 3.89%, INSILICO up 3.3%, and XTALPI up 3.52%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment